The British Medical Association has withdrawn its opposition to the Cass review of NHS gender identity services, accepting that the report's methodology was sound and dropping its objections to all 32 of its recommendations. The reversal marks a significant shift for the UK's principal doctors' union, which had previously voted to reject the review's findings outright.

The BMA's prior position was unambiguous. Its council had voted to oppose implementation of the Cass review, describing its conclusions as unsubstantiated. That stance put the union at odds with a body of work that took four years to complete and drew on data from 113,000 children. For a professional body of the BMA's standing to dismiss those findings so categorically made its reversal, when it came, all the more consequential.

The review itself, led by Dr Hilary Cass and published in April 2024, concluded that NHS gender medicine had been built on insufficient evidence. Children and young people, it found, had been failed by a lack of rigorous research into the medical interventions being offered to them. The report also identified a pattern in which young patients presenting with complex needs, including depression, self-harm and histories of trauma, were sometimes directed toward clinical treatment pathways before those underlying conditions had been properly assessed.

The BMA's reassessment was conducted by a panel of 12 union members led by Professor David Strain, chair of the BMA's board of science. Strain said the group had included clinicians with differing perspectives on the subject, and that despite variation in policy preferences, there had been agreement on the integrity of the data underpinning the Cass report. The panel's conclusion was that the methodology was robust. The BMA is no longer opposed to any of the review's recommendations.

Strain acknowledged the difficulty of the clinical territory. He noted that the report highlighted the challenge of managing genuine uncertainty when treating patients with gender incongruence, and that improvements were needed in how gender identity services for children and young people were structured and delivered. Those observations broadly align with what Cass herself argued, and their endorsement by the BMA closes a chapter of institutional disagreement that had complicated the review's reception within parts of the medical profession.

Where the BMA has not shifted is on the government's decision to ban puberty blockers on the NHS. The union accepted the Cass review's finding that there was insufficient evidence to support prescribing sex hormones to under-18s, but argued that the legislative ban went further than the review had recommended. Its position is that banning specific drugs through political rather than clinical channels is an infringement on prescribing autonomy. Doctors, the union argued, are trained to make exactly these judgements, and removing that discretion by statute sets a problematic precedent regardless of the specific clinical question involved.

The distinction matters. The BMA is not disputing the evidentiary basis of the Cass review. It is disputing the government's decision to convert clinical uncertainty into a blanket legal prohibition. Those are different arguments, and conflating them would obscure what the BMA has and has not conceded.

The institutional consequences of the review have already taken effect. The Tavistock clinic in London, which operated as the NHS's only gender identity development service for children and young people, was permanently closed in March 2024. Between 2009 and 2020 the clinic had treated around 9,000 patients, with an average referral age of 14. Its closure preceded the BMA's revised position by two years.

The BMA's change of stance removes one of the more visible points of resistance to the Cass review's broader acceptance within the medical establishment. Whether that translates into smoother implementation of the review's remaining recommendations will depend on how the government, NHS England and the clinical workforce navigate the continuing disagreement over puberty blockers, where the argument has shifted from the science to the proper limits of legislative authority over medical practice.

‍